Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles.
Journal Article (Journal Article)
Measles remains a principal cause of worldwide mortality, in part because young infants cannot be immunized effectively. Development of new vaccines has been hindered by previous experience with a formalin-inactivated vaccine that predisposed to a severe form of disease (atypical measles). Here we have developed and tested potential DNA vaccines for immunogenicity, efficacy and safety in a rhesus macaque model of measles. DNA protected from challenge with wild-type measles virus. Protection correlated with levels of neutralizing antibody and not with cytotoxic T lymphocyte activity. There was no evidence in any group, including those receiving hemagglutinin-encoding DNA alone, of 'priming' for atypical measles.
Full Text
Duke Authors
Cited Authors
- Polack, FP; Lee, SH; Permar, S; Manyara, E; Nousari, HG; Jeng, Y; Mustafa, F; Valsamakis, A; Adams, RJ; Robinson, HL; Griffin, DE
Published Date
- July 2000
Published In
Volume / Issue
- 6 / 7
Start / End Page
- 776 - 781
PubMed ID
- 10888926
International Standard Serial Number (ISSN)
- 1078-8956
Digital Object Identifier (DOI)
- 10.1038/77506
Language
- eng
Conference Location
- United States